Contents 1 Instructions for genetically recombinant human brain natriuretic peptide 1.1 Drug name 1.2 English name 1.3 Alias ??of brain natriuretic peptide 1.4 Classification 1.5 Dosage form 1.6 Pharmacological effects of genetically recombinant human brain natriuretic peptide 1.7 Genetically recombinant human brain Pharmacokinetics of natriuretic peptides 1.8 Indications of genetically recombinant human brain natriuretic peptide 1.9 Contraindications of genetically recombinant human brain natriuretic peptide 1.10 Usage and dosage of genetically recombinant human brain natriuretic peptide This is a redirect entry, ** *Shared the content of genetically recombinant human brain natriuretic peptide. For the convenience of reading, the genetic recombinant human brain natriuretic peptide below has been automatically replaced by brain natriuretic peptide. You can click here to restore the original appearance, or use the note method to display 1 Brain Natriuretic Peptide Instructions 1.1 Drug Name
Brain natriuretic peptide 1.2 English name
Rebined Human Be Natriuretic Peptide 1.3 Alias ??of brain natriuretic peptide
Nesiritide; atrial natriuretic peptide; atrial natriuretic peptide; genetically recombinant human brain natriuretic peptide Natriuretic Peptide; Nesiritide; Be Natriuretic Peptide; rhBNP 1.4 Category
Circulatory system drugs> Anti-cardiac insufficiency drugs> Other 1.5 dosage forms
0.5mg/tube.
1.6 Pharmacological effects of brain natriuretic peptide
1. Balanced expansion of arteries and veins, reduction of cardiac pre- and post-load, rapid relief of dyspnea and systemic symptoms, without drug resistance.
2. Moderate diuresis and natriuresis, reducing circulating volume load and increasing renal filtration without increasing the burden on the kidneys.
3. Comprehensively antagonize the cardiotoxicity caused by excessive activation of the neuroendocrine system.
4. Delay cardiac remodeling, prevent myocardial hypertrophy and interstitial fibrosis, and reduce long-term mortality.
5. It has no positive inotropic and positive heart rate effects, does not increase myocardial oxygen consumption, and has no arrhythmogenic effect. 1.7 Pharmacokinetics of brain natriuretic peptide
The onset of action of injection administration is 15 minutes, and the time to reach the peak reduction in pcwp is about 0.5 hours; t1/2 is about 18 minutes, and t1/2 is about 2 minutes. 1.8 Indications of brain natriuretic peptide
Acute compensated heart failure, myocardial infarction, chronic decompensated heart failure, cardiac catheterization surgery, chronic pulmonary heart disease, thoracic surgery, cardiac surgery Postoperative left heart failure with mild to moderate renal insufficiency. 1.9 Contraindications of brain natriuretic peptide
Patients who are allergic to brain natriuretic peptide, have cardiogenic shock or systolic blood pressure <90mmHg (12kPa), and patients with low cardiac filling pressure. 1.10 Usage and dosage of brain natriuretic peptide
1.5～2μg/kg, then intravenous infusion maintenance dose: 0.0075～0.01μg/(kg·min). Generally, continuous intravenous infusion is used for 24 to 48 hours, and after relief, it is changed to standard oral drugs.